Our Research and Development Pipeline
Our R&D activities are focused on:
- Cardiovascular disease
- Diabetic and metabolic disorders
- Bone/joint disease
- Infectious disease
- Cancer
- Immunological/allergic disease
The R&D budget to support the clinical development was 1.28 billion € in 2008.
The major of our pipeline compounds are listed below.
| Development code number |
Class or application |
Developmental |
| Cardiovascular | ||
|
CS - 866CMB(E) |
Hypertension |
Phase III |
|
CS - 8635 |
Hypertension |
Phase III |
|
DU - 176b |
Oral anticoagulant (Factor Xa Inhibitor) |
Phase II |
|
CS - 8080 |
Atherosclerosis |
Phase I |
| Diabetes | ||
|
AJD 101 |
Diabetes (Oral insulin mimetic) |
Phase II |
| Cancer | ||
|
CS - 7017 |
Oncology (PPAR gamma agonist) |
Phase I |
|
CS - 1008 |
Oncology (DR5 antibody) |
Phase II |
| Immune Disorders / Autoimmunity | ||
|
CS - 0777 |
Immunomodulator (S1P1 Modulator) |
Phase I |
